Daintain/AIF-1 accelerates the activation of insulin-like growth factor-1 receptor signaling pathway in HepG2 cells

Jia,Shaohui; Du,Zhongxia; Jiang,Hua; Huang,Xingyuan; Chen,Zhengwang; Chen,Ning

doi:10.3892/or.2015.4002

Daintain/AIF-1 accelerates the activation of insulin-like growth factor-1 receptor signaling pathway in HepG2 cells

Authors:
- Shaohui Jia
- Zhongxia Du
- Hua Jiang
- Xingyuan Huang
- Zhengwang Chen
- Ning Chen
View Affiliations

Affiliations: College of Health Science, Wuhan Sports University, Wuhan, Hubei 430079, P.R. China, Key Laboratory of Molecular Biophysics of the Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, Hubei 430074, P.R. China, School of Life Science and Technology, Hubei Engineering University, Xiaogan, Hubei 432000, P.R. China
Published online on: May 20, 2015 https://doi.org/10.3892/or.2015.4002
Pages: 511-517

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Daintain/allograft inflammatory factor-1 (AIF-1), as a novel inflammatory factor, has been reported to accelerate the proliferation and migration of breast cancer cells. However, the effect of daintain/AIF-1 on hepatocarcinogenesis remains unclear. In order to explore the effect of daintain/AIF-1 on the progression of hepatocellular carcinoma (HCC), enzyme-linked immunosorbent assay (ELISA) and reverse transcription polymerase chain reaction (RT-PCR) were performed to examine the secretion and gene expression of (IGF)-1, IGF-2 and IGFBP-3. The expression of IGF-1R and its downstream targets was evaluated by western blotting. In addition, the proliferation and cell‑cycle progression of HepG2 cells was assessed by 3-(4,5-dimethylthiazol-2-yl)‑2,5-diphenylterazolium bromide (MTT) and flow cytometric analysis. The results showed that HepG2 cells subjected to daintain/AIF-1 treatment revealed an obvious increase in the secretion of IGF-1 and IGF-2, and a reduction in the secretion of IGFBP-3. Moreover, daintain/AIF-1 accelerated the activation of IGF-1-induced IGF-1R and its downstream AKT signaling pathway, and subsequently promoted the activation of cyclin D1 pathway, thus accelerating the progression of the cell cycle and eventually promoting the proliferation of HepG2 cells. In conclusion, daintain/AIF-1 promoted the proliferation of HepG2 cells by accelerating the activation of IGF-1R and its downstream signaling pathway, which confirms that daintain/AIF-1 plays a crucial role in the development of HCC.

View Figures

View References

1	Bosch FX, Ribes J, Díaz M and Cléries R: Primary liver cancer: worldwide incidence and trends. Gastroenterology. 127(Suppl 1): S5–S16. 2004. View Article : Google Scholar : PubMed/NCBI
2	LeRoith D and Roberts CT Jr: The insulin-like growth factor system and cancer. Cancer Lett. 195:127–137. 2003. View Article : Google Scholar : PubMed/NCBI
3	Pollak MN, Schernhammer ES and Hankinson SE: Insulin-like growth factors and neoplasia. Nat Rev Cancer. 4:505–518. 2004. View Article : Google Scholar : PubMed/NCBI
4	Khandwala HM, McCutcheon IE, Flyvbjerg A and Friend KE: The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev. 21:215–244. 2000. View Article : Google Scholar : PubMed/NCBI
5	Baserga R: Oncogenes and the strategy of growth factors. Cell. 79:927–930. 1994. View Article : Google Scholar : PubMed/NCBI
6	Reynolds AR and Kyprianou N: Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting. Br J Pharmacol. 147(Suppl 2): S144–S152. 2006. View Article : Google Scholar : PubMed/NCBI
7	Scharf JG and Braulke T: The role of the IGF axis in hepatocar-cinogenesis. Horm Metab Res. 35:685–693. 2003. View Article : Google Scholar
8	Alexia C, Fallot G, Lasfer M, Schweizer-Groyer G and Groyer A: An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochem Pharmacol. 68:1003–1015. 2004. View Article : Google Scholar : PubMed/NCBI
9	Chen ZW, Ahren B, Ostenson CG, Cintra A, Bergman T, Möller C, Fuxe K, Mutt V, Jörnvall H and Efendic S: Identification, isolation, and characterization of daintain (allograft inflammatory factor 1), a macrophage polypeptide with effects on insulin secretion and abundantly present in the pancreas of prediabetic BB rats. Proc Natl Acad Sci USA. 94:13879–13884. 1997. View Article : Google Scholar
10	Utans U, Arceci RJ, Yamashita Y and Russell ME: Cloning and characterization of allograft inflammatory factor-1: a novel macrophage factor identified in rat cardiac allografts with chronic rejection. J Clin Invest. 95:2954–2962. 1995. View Article : Google Scholar : PubMed/NCBI
11	Tian Y, Kelemen SE and Autieri MV: Inhibition of AIF-1 expression by constitutive siRNA expression reduces macrophage migration, proliferation, and signal transduction initiated by atherogenic stimuli. Am J Physiol Cell Physiol. 290:C1083–C1091. 2006. View Article : Google Scholar
12	Yang ZF, Ho DW, Lau CK, Lam CT, Lum CT, Poon RT and Fan ST: Allograft inflammatory factor-1 (AIF-1) is crucial for the survival and pro-inflammatory activity of macrophages. Int Immunol. 17:1391–1397. 2005. View Article : Google Scholar : PubMed/NCBI
13	Kimura M, Kawahito Y, Obayashi H, Ohta M, Hara H, Adachi T, Tokunaga D, Hojo T, Hamaguchi M, Omoto A, et al: A critical role for allograft inflammatory factor-1 in the pathogenesis of rheumatoid arthritis. J Immunol. 178:3316–3322. 2007. View Article : Google Scholar : PubMed/NCBI
14	Del Galdo F, Maul GG, Jiménez SA and Artlett CM: Expression of allograft inflammatory factor 1 in tissues from patients with systemic sclerosis and in vitro differential expression of its isoforms in response to transforming growth factor beta. Arthritis Rheum. 54:2616–2625. 2006. View Article : Google Scholar : PubMed/NCBI
15	Pashenkov M, Efendic S, Zhu J, Zou LP, Ostenson CG and Mustafa M: Augmented expression of daintain/allograft inflammatory factor-1 is associated with clinical disease: dynamics of daintain/allograft inflammatory factor-1 expression in spleen, peripheral nerves and sera during experimental autoimmune neuritis. Scand J Immunol. 52:117–122. 2000. View Article : Google Scholar : PubMed/NCBI
16	Liu S, Tan WY, Chen QR, Chen XP, Fu K, Zhao YY and Chen ZW: Daintain/AIF-1 promotes breast cancer proliferation via activation of the NF-kappaB/cyclin D1 pathway and facilitates tumor growth. Cancer Sci. 99:952–957. 2008. View Article : Google Scholar : PubMed/NCBI
17	Li T, Feng Z, Jia S, Wang W, Du Z, Chen N and Chen Z: Daintain/AIF-1 promotes breast cancer cell migration by up-regulated TNF-α via activate p38 MAPK signaling pathway. Breast Cancer Res Treat. 131:891–898. 2012. View Article : Google Scholar
18	Balkwill F and Mantovani A: Inflammation and cancer: back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
19	Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM and Karin M: Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 317:121–124. 2007. View Article : Google Scholar : PubMed/NCBI
20	Fausto N, Campbell JS and Riehle KJ: Liver regeneration. Hepatology. 43(Suppl 1): S45–S53. 2006. View Article : Google Scholar : PubMed/NCBI
21	Nagakawa Y, Nomoto S, Kato Y, Montgomery RA, Williams GM, Klein AS and Sun Z: over-expression of AIF-1 in liver allografts and peripheral blood correlates with acute rejection after transplantation in rats. Am J Transplant. 4:1949–1957. 2004. View Article : Google Scholar : PubMed/NCBI
22	Hirsch J, Hansen KC, Choi S, Noh J, Hirose R, Roberts JP, Matthay MA, Burlingame AL, Maher JJ and Niemann CU: Warm ischemia-induced alterations in oxidative and inflammatory proteins in hepatic Kupffer cells in rats. Mol Cell Proteomics. 5:979–986. 2006. View Article : Google Scholar : PubMed/NCBI
23	Huynh H, Chow PK, Ooi LL and Soo KC: A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation. Cell Growth Differ. 13:115–122. 2002.PubMed/NCBI
24	Aishima S, Basaki Y, Oda Y, Kuroda Y, Nishihara Y, Taguchi K, Taketomi A, Maehara Y, Hosoi F, Maruyama Y, et al: High expression of insulin-like growth factor binding protein-3 is correlated with lower portal invasion and better prognosis in human hepatocellular carcinoma. Cancer Sci. 97:1182–1190. 2006. View Article : Google Scholar : PubMed/NCBI
25	Lund P, Schubert D, Niketeghad F and Schirmacher P: Autocrine inhibition of chemotherapy response in human liver tumor cells by insulin-like growth factor-II. Cancer Lett. 206:85–96. 2004. View Article : Google Scholar : PubMed/NCBI
26	Firth SM and Baxter RC: Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 23:824–854. 2002. View Article : Google Scholar : PubMed/NCBI
27	Yakar S, Wu Y, Setser J and Rosen CJ: The role of circulating IGF-I: lessons from human and animal models. Endocrine. 19:239–248. 2002. View Article : Google Scholar
28	Bach LA, Headey SJ and Norton RS: IGF-binding proteins - the pieces are falling into place. Trends Endocrinol Metab. 16:228–234. 2005. View Article : Google Scholar : PubMed/NCBI
29	Adams TE, Epa VC, Garrett TP and Ward CW: Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci. 57:1050–1093. 2000. View Article : Google Scholar : PubMed/NCBI
30	Butler AA, Yakar S, Gewolb IH, Karas M, Okubo Y and LeRoith D: Insulin-like growth factor-I receptor signal transduction: at the interface between physiology and cell biology. Comp Biochem Physiol B Biochem Mol Biol. 121:19–26. 1998. View Article : Google Scholar
31	Dearth RK, Cui X, Kim HJ, Hadsell DL and Lee AV: Oncogenic transformation by the signaling adaptor proteins insulin receptor substrate (IRS)-1 and IRS-2. Cell Cycle. 6:705–713. 2007. View Article : Google Scholar : PubMed/NCBI
32	Hashemolhosseini S, Nagamine Y, Morley SJ, Desrivières S, Mercep L and Ferrari S: Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem. 273:14424–14429. 1998. View Article : Google Scholar : PubMed/NCBI
33	Chen Y, Knudsen ES and Wang JY: The RB/p107/p130 phosphorylation pathway is not inhibited in rapamycin-induced G1-prolongation of NIH3T3 cells. Oncogene. 13:1765–1771. 1996.PubMed/NCBI
34	Gao N, Flynn DC, Zhang Z, Zhong XS, Walker V, Liu KJ, Shi X and Jiang BH: G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol. 287:C281–C291. 2004. View Article : Google Scholar : PubMed/NCBI
35	Burkhart DL and Sage J: Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer. 8:671–682. 2008. View Article : Google Scholar : PubMed/NCBI
36	Santamaria D and Ortega S: Cyclins and CDKS in development and cancer: lessons from genetically modified mice. Front Biosci. 11:1164–1188. 2006. View Article : Google Scholar
37	Malumbres M and Barbacid M: Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 9:153–166. 2009. View Article : Google Scholar : PubMed/NCBI
38	Lindqvist A, Rodríguez-Bravo V and Medema RH: The decision to enter mitosis: feedback and redundancy in the mitotic entry network. J Cell Biol. 185:193–202. 2009. View Article : Google Scholar : PubMed/NCBI
39	Schuuring E, Verhoeven E, Mooi WJ and Michalides RJ: Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas. Oncogene. 7:355–361. 1992.PubMed/NCBI